Quick Takeaways
- This page summarizes David E. Lazar's Form 4 filing for Cyclacel Pharmaceuticals, Inc. (CYCC).
- 1 reported transaction and 0 derivative rows are listed below.
- Filing timestamp: 04 Aug 2025, 19:23.
David E. Lazar - 30 Jul 2025 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)
- Role
- 10%+ Owner
- Signature
- /s/ David E. Lazar
- Issuer symbol
- CYCC
- Transactions as of
- 30 Jul 2025
- Net transactions value
- -$83,430
- Form type
- 4
- Filing time
- 04 Aug 2025, 19:23:01 UTC
- Previous filing
- 07 Apr 2025
- Next filing
- 26 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"David E. Lazar filed Form 4 for Cyclacel Pharmaceuticals, Inc. (CYCC) on 04 Aug 2025."
What Changed
- Previous filing in this sequence was filed on 07 Apr 2025.
- Current net transaction value: -$83,430.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Lazar David E. | 10%+ Owner | PH THE TOWERS, TOWER 200, 30B, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA | /s/ David E. Lazar | 04 Aug 2025 | 0001932843 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | CYCC | Common Stock | Sale | $83,430 | -6,750 | -4.2% | $12.36* | 155,838 | 30 Jul 2025 | Direct | F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
David E. Lazar is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The number Shares owned by the Reporting Person is reflective of a 1-for-15 reverse stock split effected by the Issuer on July 7, 2025 (the "Reverse Stock Split"). |
| F2 | Due to an inadvertent ministerial error, the Form 4 filed by the Reporting Person on February 28, 2025 reported beneficial ownership of 354,738 shares of the Issuer's Series D Convertible Preferred Stock which had already been converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of such date. |
Remarks:
This filing constitutes an exit filing for the Reporting Person, as the Reporting Person is no longer subject to Section 16 of the Exchange Act as a result of the sale described above.